Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/219680
Title: | The polygenic basis of relapse after a first episode of schizophrenia |
Author: | Segura, Alex G. Prohens, Llucia Gassó Astorga, Patricia Rodríguez Ferret, Natalia García Rizo, Clemente Moreno-Izco, Lucía Andreu-Bernabeu, Álvaro Zorrilla, Iñaki Mané Santacana, Anna Rodriguez Jimenez, Roberto Roldán Bejarano, Alexandra Sarró, Salvador Ibáñez, Ángela Usall i Rodié, Judith Sáiz, Pilar A Cuesta, Manuel J. Parellada, Mara González-Pinto, Ana Berrocoso, Esther Bernardo Arroyo, Miquel Mas, Sergi Mezquida Mateos, Gisela Arbelo, Néstor De Matteis, Mario Galvañ, Joaquin Duque Guerra, Alejandra Arias i Queralt, Laia Pérez Bacigalupe, María González Ortega, Itxaso Toll Privat, Alba Casanovas Martínez, Francesc Sanchez Pastor, Luis Valtueña, Mercedes Pomarol-Clotet, Edith García León, María Ángeles Butjosa Molines, Anna Rubio Abadal, Elena Ribeiro, María López-Ilundain, Jose M. Saiz Ruiz, Jerónimo León-Quismondo, Luis Rivero, Olga Ruiz, Pedro Segarra Echevarría, Rafael García-Portilla González, María Paz, 1962- |
Keywords: | Cognició Malalties hereditàries Esquizofrènia Cognition Genetic diseases Schizophrenia |
Issue Date: | 19-Aug-2023 |
Publisher: | Elsevier B.V. |
Abstract: | Little is known about genetic predisposition to relapse. Previous studies have linked cognitive and psychopathological (mainly schizophrenia and bipolar disorder) polygenic risk scores (PRS) with clinical manifestations of the disease. This study aims to explore the potential role of PRS from major mental disorders and cognition on schizophrenia relapse. 114 patients recruited in the 2EPs Project were included (56 patients who had not experienced relapse after 3 years of enrollment and 58 patients who relapsed during the 3-year follow-up). PRS for schizophrenia (PRS-SZ), bipolar disorder (PRS-BD), education attainment (PRS-EA) and cognitive performance (PRS-CP) were used to assess the genetic risk of schizophrenia relapse.Patients with higher PRS-EA, showed both a lower risk (OR=0.29, 95% CI [0.11-0.73]) and a later onset of relapse (30.96± 1.74 vs. 23.12± 1.14 months, p=0.007. Our study provides evidence that the genetic burden of neurocognitive function is a potentially predictors of relapse that could be incorporated into future risk prediction models. Moreover, appropriate treatments for cognitive symptoms appear to be important for improving the long-term clinical outcome of relapse. |
Note: | Reproducció del document publicat a: https://doi.org/10.1016/j.euroneuro.2023.06.003 |
It is part of: | European Neuropsychopharmacology, 2023, vol. 75, p. 80-92 |
URI: | https://hdl.handle.net/2445/219680 |
Related resource: | https://doi.org/10.1016/j.euroneuro.2023.06.003 |
ISSN: | 0924-977X |
Appears in Collections: | Articles publicats en revistes (Fonaments Clínics) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
828479.pdf | 927.68 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License